Summary This study evaluates the cell surface expression of urokinase-type plasminogen activator (u-PA) and the capacity to bind exogenous urokinase as possible parameters for the distinction of various types of human lung tumours. Twelve different tumour cell lines including four small cell carcinoma, two large cell carcinoma, three squamous cell carcinoma, one adenocarcinoma and two mesothelioma cell lines of lung origin were investigated. Surface expression of endogenous u-PA was determined in a cellular radioimmunoassay (CRIA) using the u-PA-specific monoclonal antibody 98/6. To estimate additional u-PA binding capacity, exogenous two-chain, 54 kDa u-PA was employed in the CRIA. The influence of phorbol ester (PMA) treatment on expression and binding of these molecules was studied. Three different groups of lung tumour cell lines could be distinguished according to their expression of u-PA and u-PA-binding ability: (i) non small cell lung carcinoma (NSCLC) cell lines of squamous cell carcinoma/adenocarcinoma origin expressed small amounts of u-PA and bound little u-PA. Large cell carcinoma cell lines expressed high amounts of u-PA and bound large amounts of u-PA. In general, expression of u-PA and u-PA binding was enhanced after PMA treatment. (ii) Mesothelioma cell lines did not express u-PA, but were able to bind u-PA. (iii) Small cell carcinoma (SCLC) lines were devoid of surface-expressed u-PA and could not bind u-PA, both under untreated and PMA-treated conditions. It could thus be demonstrated that these three groups of lung tumour cell lines differ in their ability to express u-PA and to bind external u-PA. This may reflect the different in vivo growth behaviour and origin of the respective tumour groups.
Based on characteristic histological structures, human lung tumours can be classified into two major groups: NSCLC (squamous cell carcinoma, adenocarcinoma, large cell carcinoma) and SCLC, SCLC can be distinguished from NSCLC by their clinical behaviour, the occurrence of metastases at very early stages of tumour development and certain serological parameters (Gazdar et al., 1981; World Health Organisation, 1982) . The biological mechanisms underlying the different metastatic behaviour of these tumour groups are poorly understood.
Since several studies suggested a contribution of plasminogen activators (PA) in tumour invasion and in the formation of distant metastases (Dan0 et al., 1986; Ossowski & Reich, 1983) , we investigated the PA-system in human lung tumour lines in order to better understand the biological basis of these malignancies and to use this enzyme system as possible means to differentiate human lung tumours.
PA-mediated proteolysis may cause degradation of structural constituents of the extracellular matrix (ECM) which may result in a facilitated intra-and extravasation of tumour cells during metastasis formation.
For a more comprehensive evaluation of the relationship between tumour malignancy and PA activity, other components of this enzyme system as, for instance, plasminogen activator inhibitors (PAI) (Cwikel et al., 1984; Eaton & Baker, 1983; Genton et al., 1987) as well as the microenvironment, have to be considered. For instance, growth factors like epidermal growth factor (EGF) and transforming growth factor-, (TGF-,B) are known to regulate synthesis and secretion of both proteolytic and inhibitory components of the PA system (Keski-Oja et al., 1988; Lee & Weinstein, 1978) . In a previous study we analysed both PA and PAI in human lung tumour lines of different origin (Heidtmann et al., 1989) . We found that cell lines of NSCLC origin produced and secreted PA of u-PA and t-PA type and PAI in various amounts and combinations. Strikingly, cell lines of SCLC and mesothelioma origin were not able to produce any protein of the PA system. NSCLC cell lines generally showed increased PA activity when treated with EGF and reduced PA activity and enhanced formation of PA/PAI-complexes when treated with TGF-P. SCLC cell lines did not respond to these growth factors (non published data).
PA may not only be effective in tumour-associated degradation processes by a secreted but also by a cell surfacebound form. Receptors for u-PA have been described for several cell types, as for instance for monocytes and the monocytic cell line U937 (Plow et al., 1986; Stoppelli et al., 1985; Vassalli et al., 1985) , the foetal lung fibroblast cell line GM 1380 (Plow et al., 1986) , and the human carcinoma cell line A431 (Stoppelli et al., 1986) . Recently, a 55 kDa glycoprotein was characterised as an u-PA receptor in cloning and transfectant studies (Roldan et al., 1990) . It may well be that tumour cells synthesise little or no u-PA, but may have unoccupied u-PA binding sites which enable them to use external u-PA for degradation processes.
While the autocrine binding of biosynthetic pro-u-PA to the u-PA receptor is well established (Stoppelli et al., 1986) , binding mechanisms of exogenous u-PA to epithelial cells require closer investigation. For example, several studies indicate an involvement of surface-located proteinase inhibitors, such as PAI-I and Protease-Nexin (Baker et al., 1980) , in the complexation and processing of u-PA. In a first attempt to study these questions in human lung tumours, we determined the presence of cell surfaceexpressed u-PA and the capacity to bind exogenous u-PA on human lung tumour lines of NSCLC, SCLC and mesothelioma origin. We also applied PMA in our investigations, since it has been shown to be a potent stimulator of the PA system in various cell types (Eaton & Baker, 1983; Heidtmann et al., 1989; Lee & Weinstein, 1978) . By measuring these parameters, three groups of human lung tumour cell lines could be distinguished.
In addition to synthesis and expression of constituents of the PA system, u-PA surface binding may represent a further component to distinguish mesothelioma cell lines from NSCLC and SCLC cell lines. SCLC cell lines, although derived from highly metastatic tumours, were found to be totally deficient of the PA system. The PA system may play a role in the metastatic process of NSCLC and, in an indirect way, mesotheliomas of the lung. As control antibodies we applied MAb HEA 125 recognising an epithelium-specific surface glycoprotein of 34 kDa Momburg et al., 1987) and MAb HD37 recognising the B lymphocyte-specific differentiation antigen CD19 (Pezzutto et al., 1986) .
Cell lines and cell culture conditions Cell lines EPLC-65H, EPLC-32M1 (Bepler et al., 1988) , SK-LC-LL (Fogh & Trempe, 1975) were of squamous cell origin; cell line SK-LU-1, supplied by American Type Culture Collection, was of adenocarcinoma origin; cell lines SCLC-21H, SCLC-22H, SCLC-24H, SCLC-86M1 (Bepler et al., 1987a,b) were of small cell origin; cell lines LCLC-103H, LCLC-97TM1 (Bepler et al., 1988) were of large cell origin; cell lines MSTO-21 1H (Bepler et (Greenwood et al., 1963) . In brief, 100 fig of the protein solution in 100 ftl PBS were incubated with 1 mCi of Na 1251 and 50 tlI Chloramin T (1 mg 1 mldistilled water) for 1 min at room temperature. Reaction was stopped by addition of 50 tlI sodium metabisulfite (1 mg NaS205 1 ml-' distilled water). The reaction mixture was given immediately over a ion exchange chromatography column (2 ml volume, Dowex, 200-400 mesh size, counter ion CI-), Fractions of 500 tlI were sampled and measured for radioactivity. The peak fraction was used for the cellular radioimmuno assay (CRIA). The CRIA was performed in flexible polyvinyl chloride microtiter plates, as described previously (Schwartz et al., 1985) . Plates were blocked for nonspecific binding by preincubation with PBS + 0.2% (v/v) In order to test for binding specificity of u-PA, representative cell lines of squamous cell carcinoma, large cell carcinoma, SCLC and mesothelioma were incubated with 2 x 106 c.p.m. of '25I-u-PA in the presence of unlabelled u-PA in excess (1-10ipg u-PA/I x 106 cells). Addition of 1 ig unlabelled u-PA abolished binding of 125I-u-PA to background values in all cell lines. In SCLC cell lines competition with unlabelled u-PA had no effect on the residual radioactivity bound. Unrelated proteins such as insulin or thrombin added in the same amounts as unlabelled u-PA did not affect specific binding of 125I-u-PA to the cells.
Estimation of the number of cell surface-expressed u-PA molecules was done by measuring the binding of 1251-labelled MAb 98/6 followed by Scatchard plot analysis (Scatchard, 1949) .
Western blot analysis and immunochemical staining After separation of u-PA on SDS-PAGE, both under reducing and non-reducing conditions, the electrophoretic transfer 
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of u-PA to nitrocellulose was performed at 5 V cm-' overnight at 4°C as described (Towbin et al., 1979 (Table I) (Heidtmann et al., 1989) .
To assess the number of u-PA molecules present on the surface of viable cells, we performed Scatchard plot analyses. For example, cell line EPLC 32M I expressed approx 3.6 x 10o u-PA molecules/cell under normal cell culture conditions and approx 1.6 x 105 u-PA molecules/cell after PMA treatment ( Figure 2 ). As expected from CRIA results, cell line LCLC 103H expressed more u-PA molecules than the squamous cell carcinoma cell lines (approx 1.88 x 106 molecules/cell untreated and approx 1.9 x 106 molecules/cell after treatment with PMA).
The epithelium-specific MAb HEA 125 was applied in the CRIA as positive control MAb for epithelial cells. This MAb had previously been shown to react with NSCLC cell lines and in an even stronger fashion with SCLC cell lines . These results could be affirmed in the CRIA performed for this study. In all epithelial cell lines expression of the HEA 125 antigen was unchanged or even reduced after PMA treatment.
Cell surface binding of exogenous u-PA to human lung tumour cell lines The capacity of the cell lines to bind exogenous, radioiodinated two chain (54 kDa) u-PA is given in Table III . In this CRIA, the presence of unoccupied binding sites for u-PA was determined. Squamous/adenocarcinoma and large cell carcinoma cell lines expressed endogenous u-PA at the surface as shown in Table II . Additionally, these cell lines had free binding capacity for u-PA. Both LCLC cell lines showed (Pezzutto et al., 1986) and was subtracted from values of MAb 98/6 binding. As positive control MAb HEA 125, an epithelium-specific marker, was used .
Both mesothelioma cell lines were negative for HEA 125 expression. The experiment was carried out three times with essentially identical results. SCLC cell lines and mesothelioma cell lines were regarded as negative for mAb98/6 binding. These cell lines were shown to be negative for u-PA synthesis (Heidtmann et al., 1989) . duce u-PA (Heidtmann et al., 1989) , were able to bind exogenous u-PA in amounts comparable to those of squamous cell carcinoma lines. Also, PMA enhanced binding of u-PA in these cells. In contrast to the findings of other groups, who investigated the nature of the u-PA receptor, (Plow et al., 1986; Stoppelli et al., 1986 ) labelled u-PA could not be replaced by unlabelled u-PA (applied in the range of 10 gg-0.001 ILg well) when unlabelled u-PA was added to the cells after 60min incubation with '25I-u-PA. This result was observed with squamous cell carcinoma and mesothelioma cell lines, both untreated and treated with PMA. Since binding of u-PA to the cells was irreversible, it did not seem to be mediated by the u-PA receptor described earlier (Stoppelli et al., 1985) .
We tentatively conclude that surface binding of exogenous, two-chain u-PA occurs via an irreversible, presumably covalent, complex with a yet unknown surface protein. Further biochemical characterisation of this complex, which will be published elsewhere, supports this notion. This irreversible complex formation may also explain why Scatchard plot analysis of exogenous '25I-labelled u-PA binding did not results in a linear function.
In kinetic experiments maximum binding of external u-PA was achieved after a 60 min incubation period at room temperature for NSCLC and mesothelioma cell lines ( Figure  3 ).
Estimation of u-PA binding sites on the surface of cell line CH3LC being devoid of endogenous u-PA Since cell lines of mesothelioma origin were the only ones studied here which did not produce u-PA, but were able to bind exogenous u-PA, we closer examined the capacity of these cells to bind u-PA. For this purpose, CH3LC cells were preincubated with unlabelled u-PA (1O jig/l x 106 cells) for These results are in keeping with and extend previous observations (Heidtmann et al., 1989) . In the earlier study we found that NSCLC cell lines could produce u-PA along with other components of the PA system, whereas SCLC and mesothelioma cell lines were deficient in the synthesis of any protein of the PA system. The finding that mesothelioma cell lines are able to bind u-PA despite of their deficiencies for the synthesis of PA may add a new parameter for the differentiation of these lung tumours. It also demonstrates that lung tumours of different origin produce the components of the PA system and proteins of functional context in various combinations which may ensue a different response to signals of the microenvironment. For example by means of free u-PA binding sites, mesothelioma cells could make use of u-PA secreted by other cells. Since SCLC cell lines were deficient of any constituent of the PA system and unresponsive to treatment with PMA or growth factors, the high malignancy of this tumour class may not be correlated to a tumour-associated proteolytic activity of the PA system. It may however well be that other proteinases or proteinases of tumour-infiltrating normal cells play a role in the invasive process of SCLC.
In an earlier study, Markus et al., 1980 investigated human lung tumour tissue for its content of plasminogen activator. No significant correlation was observed between the histopathological types and grades of malignancy of squamous cell carcinoma, adenocarcinoma and anaplastic carcinoma and the overall content of u-PA in these tissues. The u-PA producing cells were not defined in this study. Normal cells present in tumour tissues, as for example macrophages (Neumann & Sorge, 1983) and granulocytes (Granelli-Piperno et al., 1977) , are known to produce large amounts of u-PA. Indeed, recently it was reported that, when examining tumour tissue, colon carcinoma cells did not produce m-RNA for u-PA. Increased levels of u-PA-specific m-RNA were however found in interstitial stromal cells at invasive foci. Furthermore, some tumours cells were found to produce m-RNA specific for the u-PA receptor (Pyke et al., 1991) . It may well be that tumour cells, deficient of PA production, stimulate normal cells of the environment to increased proteolytic activity. The expression of the u-PA receptor or other, not yet defined binding structures for u-PA, may enable these tumour cells to direct PA activity, present in the microenvironment, to sites of invasive growth. If this were the case, one would expect to find u-PA in close association with tumour cells within tumour tissue. However, immunohistological examination of colon carcinoma tissue, using specific MAb against u-PA, failed to detect u-PA located on or close to the tumour cells (Gr0ndahl-Hansen et al., 1991) . Therefore, the function of u-PA binding sites on tumour cells, deficient of the PA system, remains obscure at the moment. It has been reported by several authors that pro-u-PA binds to a specific surface receptor (Stoppelli et al., 1986; Vassalli et al., 1985) . The binding of active two-chain u-PA to the cell surface is still a matter of controversy. Although PA activity can be measured on cells, this does not unequivocally prove the binding of active u-PA to specific receptors. Rapid conversion of receptor-bound pro-u-PA to active u-PA may also occur. On the other hand, u-PA has been demonstrated to form irreversible complexes with plasminogen activator inhibitors, as e.g. PAI-I (Hebert & Baker, 1988) and protease nexin (Howard & Knauer, 1987) which may also be situated on the cell surface via a nexin-binding protein.
NSCLC cell lines had binding sites which were occupied with endogenous u-PA. Since MAb 98/6 does not differentiate between pro-u-PA and active u-PA, surface staining by this antibody may indicate expression of both forms of u-PA and, consequently specific u-PA receptors and other proteins with binding capacity for u-PA. Mesothelioma cells-had amounts of bindin sites (Figure 4 ) comparable to those of squamous cell carcinoma cell lines (Figure 2 ), which however additionally expressed endogenous u-PA. It may therefore be that exogenous, active u-PA binds to a type of structure, present on both cell types, which is not involved in binding of endogenous pro-u-PA. NSCLC cell lines had free binding capacity which could be occupied by exogenous u-PA.
Competition of unlabelled u-PA after consecutive addition did not result in a replacement of labelled u-PA. This is in contrast to earlier studies which found reversible binding of pro-u-PA to its specific receptor with a low dissociation rate (Stopelli et al., 1985) . Further biochemical analysis of cellbound exogenous u-PA on lung tumour cells supports our notion that active u-PA forms an irreversible complex with a yet undefined protein (manuscript in preparation).
This study along with our previous ones concerning the PA system of human lung tumour cell lines indicates the possibility that the PA system is differently expressed in various groups of lung tumours. For a comprehensive evaluation of the functional role of the PA systems, all components of plasminogen activation and inhibtion as well as surface binding sites and the influence of growth factors on the entire system have to be taken into account. Furthermore, to understand in situ tumour-microenvironment interactions, it will be necessary to transfer these insights to the investigation of native tumour samples.
